Real-world clinical outcomes of treatment with molnupiravir for patients with mild-to-moderate coronavirus disease 2019 during the Omicron variant pandemic
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
It is unclear whether molnupiravir has a beneficial effect on vaccinated patients infected with the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We here evaluated the efficacy of molnupiravir in patients with mild-to-moderate coronavirus disease 2019 (COVID-19) during the Omicron variant surge in Fukushima Prefecture, Japan. We enrolled patients with mild-to-moderate COVID-19 who were admitted to hospitals between January and April, 2022. Clinical deterioration after admission was compared between molnupiravir users (n = 230) and non-users (n = 690) after 1:3 propensity score matching. Additionally, we performed forward stepwise multivariate logistic regression analysis to evaluate the association between clinical deterioration after admission and molnupiravir treatment in the 1:3 propensity score-matched subjects. The characteristics of participants in both groups were balanced as indicated by covariates with a standardized mean difference of < 0.1. Regarding comorbidities, there was no imbalance between the two groups, except for the presence of hypertension, dyslipidemia, diabetes mellitus, and cardiac disease. The clinical deterioration rate was significantly lower in the molnupiravir users compared to the non-users (3.90% vs 8.40%; P = 0.034). Multivariate logistic regression analysis demonstrated that receiving molnupiravir was a factor for preventing deterioration (odds ratio 0.448; 95% confidence interval 0.206-0.973; P = 0.042), independent of other covariates. This real-world study demonstrates that molnupiravir contributes to the prevention of deterioration in COVID-19 patients after hospitalization during the Omicron variant phase.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Real-world clinical outcomes of treatment with molnupiravir for patients with mild-to-moderate coronavirus disease 2019 during the Omicron variant pandemic
- Date Crossref
- 05/12/2022
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Fukushima Medical University Department of General Internal Medicine and Clinical Infectious Diseases pays non établi dans la noticeUniversité ou école supérieure
-
Seirei Hamamatsu General Hospital pays non établi dans la noticeÉtablissement de santé
-
Ohara General Hospital Department of Pulmonary Medicine pays non établi dans la noticeÉtablissement de santé
-
Tokushima Red Cross Hospital pays non établi dans la noticeÉtablissement de santé
-
Fujita General Hospital Department of Internal Medicine pays non établi dans la noticeÉtablissement de santé
-
Fukushima Medical University Hospital pays non établi dans la noticeÉtablissement de santé
-
Gunma Chuo Hospital pays non établi dans la noticeÉtablissement de santé
-
Ijinkai Takeda General Hospital Department of Internal Medicine pays non établi dans la noticeÉtablissement de santé
-
Takeda General Hospital pays non établi dans la noticeÉtablissement de santé
-
Sendai Kousei Hospital pays non établi dans la noticeÉtablissement de santé
-
Iwaki City Medical Center Department of Pediatric Surgery pays non établi dans la noticeÉtablissement de santé
-
Toshima Hospital pays non établi dans la noticeÉtablissement de santé
Department of General Internal Medicine and Clinical Infectious Diseases — Fukushima Medical University, Seirei Hamamatsu General Hospital et Department of Pulmonary Medicine — Ohara General Hospital, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.